Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for Melt-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
Melt製藥報告了Melt-300的三期臨床試驗結果，顯示該產品作爲無阿片類藥物的舌下程序麻醉，對進行白內障手術的患者具有良好療效。
